Predict your next investment

SynDevRx company logo
HEALTHCARE | Drug Development
syndevrx.com

See what CB Insights has to offer

Founded Year

2007

Stage

Debt - III | Alive

Total Raised

$34.61M

Last Raised

$14.67M | 2 yrs ago

About SynDevRx

SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market, and inhibits MetAP2 - an enzyme which independent research has shown to be key to tumor growth, proliferation and metastasis.

SynDevRx Headquarter Location

One Broadway 14th Floor

Cambridge, Massachusetts, 02142,

United States

617-401-3110

Latest SynDevRx News

SynDevRx Announces Research Collaboration with Queensland University of Technology (QUT) to Study the Effects of SDX-7320 In Advanced Prostate Cancer Models

Dec 10, 2021

Search jobs 07-Dec-2021 SynDevRx Announces Research Collaboration with Queensland University of Technology (QUT) to Study the Effects of SDX-7320 In Advanced Prostate Cancer Models   Part of an ongoing investigation focused on how obesity and dysregulated metabolic hormones promote prostate cancer progression and metastasis Studies aim to quantify the ability of SynDevRx MetAP2 inhibitor evexomostat (SDX-7320) to control tumor growth of castration resistant prostate cancers CAMBRIDGE--( December 7, 2021 )—SynDevRx, Inc., a clinical-stage biotechnology company leading the development in treatments for obesity-accelerated cancers, today announced a research collaboration with Australia’s Queensland University of Technology. The collaboration with Professor Colleen Nelson, PhD, and her team will study the role of methionine aminopeptidase 2 (MetAP2) inhibition in tumor growth in castration resistant and other treatment resistant forms of prostate cancer. Obesity and systemic metabolic dysfunction like pre-diabetes and type 2 diabetes are known to make many solid tumors more aggressive, including prostate cancer. MetAP2 inhibitors, such as evexomostat (SDX-7320), have been clinically shown to improve systemic metabolic hormone dysregulation1 and to possess direct anti-tumor, anti-metastatic and anti-angiogenic properties2. This combination of attributes may be well suited to sever the link between metabolic dysfunction and cancer, and may prove to be effective in treating advanced prostate cancer in combination with standard-of-care therapies. Professor Nelson is the founder and executive director of the Australian Prostate Cancer Research Centre - Queensland (APCRC-Q) and Chair of Prostate Cancer Research at Queensland University of Technology (QUT). APCRC-Q, is one of the leading global research facilities investigating the connection between prostate cancer and dysregulated metabolic hormones and pathways, and how these affect prostate cancer progression and metastasis. “The downstream effects of obesity change the tumor microenvironment in ways highly favorable to prostate cancer recurrence, progression and metastasis. Hyperleptinemia and hyperinsulinemia are well-established, negative side effects of androgen deprivation therapy (ADT) and other treatments that block the androgen axis in prostate cancer. The APCRC-Q has been investigating this relationship using targeted drugs in preclinical models that inhibit metabolic pathways induced by ADT, through tumor promoting pathways activated systemically, and through direct tumor cell adaptation,”  said Colleen Nelson, PhD, lead investigator. “We’re very excited to study SynDevRx’s SDX-7320 inhibition of MetAP2 in our well-vetted models of treatment resistant advanced prostate cancer models.” The APCRC-Q team’s research focuses on pathways activated by ADT, including alterations in metabolism that are druggable with novel targeted agents. They recently showed that pharmacological blockade of leptin receptor or the activation of adiponectin signaling was efficacious in significantly reducing tumor burden and in delaying progression to castration resistance in animal models. The APCRC-Q team has also been targeting metabolic pathways directly through mitochondrial activity or lipid synthesis in models of CRCP and ENZ resistance. “Professor Nelson team’s work has clearly demonstrated the central role that leptin and adiponectin play in the feedback loop of androgen deprivation and results in the emergence of treatment resistance,” said Peter Cornelius, PhD, senior director of translational research at SynDevRx. “Her lab has some of the best models for studying the deleterious effects of inhibition of the androgen receptor axis in prostate cancer, identifying mechanisms of resistance and then targeting those proteins driving the resistance in pre-clinical prostate cancer models. Given our clinical results showing evexomostat (SDX-7320) significantly lowers leptin and increases adiponectin in late-stage cancer patients, we’re thrilled to work with Professor Nelson and her expert team on testing the potential beneficial effects that SDX-7320/MetAP2 inhibition could play in these validated models.” “SynDevRx is establishing global collaborations with leading research institutions focused on the downstream effects that obesity and dysregulated metabolic hormones have on cancer progression and metastasis. We invite other researchers to work with us as we untangle these complex and critical interactions between cancer and dysregulated metabolic hormones,” said SynDevRx’s co-founder and Chief Business Officer James Shanahan. (Proietto et al., Diabetologia 2018 Sep;61(9):1918-1922) (Mann-Steinberg et al., “TNP-470: The Resurrection of the First Synthetic Angiogenesis Inhibitor.” (2008).) About SDX-7320 SynDevRx believes that evexomostat (SDX-7320) is the first drug being developed specifically for cancer patients with metabolic complications, such as obesity, diabetes, high blood glucose or HbA1c, pre-diabetes or insulin/leptin resistance. For certain tumor types, metabolic hormones stimulate oncogenic pathways, making the cancer more aggressive and deadlier. Evexomostat acts by binding irreversibly to its target enzyme MetAP2, triggering downstream improvements in the metabolic hormones insulin, leptin and adiponectin, improvements in key lipids, and inhibition of the important angiogenic proteins bFGF and VEGF-C, as was demonstrated in a Phase 1 clinical study in late-stage cancer patients. In preclinical studies, evexomostat also directly inhibited multiple cell cycle signaling pathways, provided synergistic anti-tumor effects in combination with a PI3K inhibitor, reduced angiogenesis, controlled aberrant metabolic hormone signaling, and reversed obesity-induced immune suppression within the tumor micro-environment of tumor-bearing obese mice. Evexomostat (SDX-7320) is being developed for use in combination with clinically indicated standard-of-care cancer therapies for breast and prostate cancers. About SynDevRx, Inc. SynDevRx is a privately held clinical-stage biopharmaceutical company based in Cambridge, Mass. that is leading the research and development of treatments that address the interactions between cancer and dysregulated metabolic hormones. – i.e., metabo-oncology. Obesity, pre-diabetes and type 2 diabetes are known to worsen certain cancer patients’ prognoses, but oncologists have no specific tools to treat systemic or treatment-induced metabolic complications, except for diet and exercise. SynDevRx is initiating a series of proof-of-concept clinical studies of its drug candidate evexomostat (SDX-7320) to show that improving these hormones together with effects on angiogenesis and the tumor micro-environment will result in better patient outcomes, thereby establishing a new and complementary treatment paradigm for tens of thousands of cancer patients. For more information visit www.syndevrx.com . About Queensland University of Technology, Australia Queensland University of Technology (QUT) is a major Australian university with a global outlook. Home to nearly 50,000 students, QUT provides real-world infrastructure, learning and teaching, and graduate skills to the next generation of change-makers. QUT’s vision is to be the university for the real world. For more information visit https://www.qut.edu.au/ . Editor Details

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SynDevRx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SynDevRx is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

SynDevRx Patents

SynDevRx has filed 20 patents.

The 3 most popular patent topics include:

  • Obesity
  • Diabetes
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/16/2018

7/28/2020

Experimental cancer drugs, Stereochemistry, Piperidines, Human proteins, Transcription factors

Grant

Application Date

11/16/2018

Grant Date

7/28/2020

Title

Related Topics

Experimental cancer drugs, Stereochemistry, Piperidines, Human proteins, Transcription factors

Status

Grant

SynDevRx Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SynDevRx Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.